论文部分内容阅读
目的探讨弥漫大B细胞淋巴瘤survivin表达与临床表现的关系。方法收集有完整随访资料的弥漫大B细胞性淋巴瘤(diffuse large B-cell lymphoma,DLBCL)患者128人,均有5年以上完整的随访资料。用免疫组化SP法检测其survivin表达情况,并分析其表达与临床预后的关系。结果128例DLBCL患者中有84例survivin蛋白表达阳性,阳性率为65.6%。表达阳性者与阴性者5年(overall survival,OS)分别为58.8%和18.7%,差异具有统计学意义。在淋巴瘤国际预后指数(international prognostic index,IPI)积分低危患者中,survivin表达阳性者5年总生存期OS及无病生存期(disease free survival,DFS)明显低于表达阴性者;在国际预后指标(international prognosis index,IPI)积分高危患者中,survivin表达阳性与阴性者5年OS无明显差异。结论Survivin是DLBCL的一个较有价值的预后指标,与IPI联合应用可筛选出低危患者中预后不良病例。
Objective To investigate the relationship between survivin expression and clinical manifestations in diffuse large B cell lymphoma. Methods A total of 128 patients with diffuse large B-cell lymphoma (DLBCL) who had complete follow-up data were followed up for more than 5 years. Survivin expression was detected by immunohistochemical SP method and its relationship with clinical prognosis was analyzed. Results Of 128 patients with DLBCL, 84 had survivin protein positive, with a positive rate of 65.6%. The 5-year overall survival (OS) of positive and negative patients was 58.8% and 18.7%, respectively. The difference was statistically significant. In the low-risk patients with lymphoma international prognostic index (IPI) score, the 5-year overall survival and the disease free survival (DFS) of survivin were significantly lower than those with negative prognosis. The prognostic indicators (international prognosis index, IPI) points in high-risk patients, survivin positive and negative 5-year OS no significant difference. Conclusion Survivin is a more valuable prognostic indicator of DLBCL. Combined with IPI, Survivin can screen out poor prognosis in low-risk patients.